15.9% Below Target

Bristol-Myers Squibb Company (BMY) has a consensus 12-month price target of $62.6, implying 15.9% upside from $54. The 41 analysts covering BMY see moderate appreciation potential.

BMY has a consensus rating of "Hold" based on 41 Wall Street analysts. The rating breakdown is mixed, with 20 Hold ratings making up the largest segment. The consensus 12-month price target of $62.6 implies 15.9% upside from current levels.

With a forward P/E of 8.5492x, BMY trades at a relatively low valuation. The consensus target of $62.6 implies 15.9% appreciation, suggesting meaningful undervaluation.

The most bullish Wall Street analyst has a price target of $75 for BMY, while the most conservative target is $40. The consensus of $62.6 represents the median expectation. Our quantitative valuation model projects a bull case target of $101 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

BMY is heavily covered by Wall Street, with 41 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 19 have Buy ratings, 20 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month BMY stock forecast based on 41 Wall Street analysts shows a consensus price target of $62.6, with estimates ranging from $40 (bear case) to $75 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $76, with bear/bull scenarios of $48/$101.

Our quantitative valuation model calculates BMY's fair value at $76 (base case), with a bear case of $48 and bull case of $101. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 51/100.

BMY trades at a forward P/E ratio of 8.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 15.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Wall Street analysts are optimistic on BMY, with a "Hold" consensus rating and $62.6 price target (15.9% upside). 19 of 41 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

BMY analyst price targets range from $40 to $75, a 56% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $62.6 consensus represents the middle ground. Our model's $48-$101 range provides an independent fundamental perspective.